Orally administered composition to lower serum methionine levels and method of use
A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.
1. A method for suppressing the growth of a malignancy within an individual comprising the steps of:
administering, orally, a composition comprising methioninase enzyme; and
administering, orally, fluid comprising pyridoxal-L-phosphate.
2. A method of treating insulin resistant diabetes mellitus, the method comprising the steps of:
administering, orally, a composition comprising methioninase enzyme; and
administering, orally, fluid comprising pyridoxal-L-phosphate.
3. A method of reversing age-related metabolic and tissue degenerative changes, the method comprising the steps of:
administering, orally, a composition comprising methioninase enzyme; and
administering, orally, fluid comprising pyridoxal-L-phosphate.
4. A method according to claim 1 , wherein the composition further comprises flavors, sweeteners, and binders.
5. A method according to claim 1 , wherein the fluid is a solution of pyridoxal-L-phosphate in drinking water.
6. A method according to claim 2 , wherein the composition further comprises flavors, sweeteners, and binders.
7. A method according to claim 2 , wherein the fluid is a solution of pyridoxal-L-phosphate in drinking water.
8. A method according to claim 3 , wherein the composition further comprises flavors, sweeteners, and binders.
9. A method according to claim 3 , wherein the fluid is a solution of pyridoxal-L-phosphate in drinking water.